Can-Fite plans interim analysis advance in Phase III liver cancer study
Can-Fite said it plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma, after reporting overall survival longer than anticipated in the ongoing pivotal Phase III.
Can-Fite BioPharma Ltd. said it plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma. The company is based in Ramat Gan, Israel. The notice was dated Sept.
02, 2026. Can-Fite described itself as a clinical-stage biotechnology company developing a pipeline of proprietary therapeutics.